NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $62.32 -4.53 (-6.78%) Closing price 04:00 PM EasternExtended Trading$62.79 +0.47 (+0.76%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeneDx Stock (NASDAQ:WGS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GeneDx alerts:Sign Up Key Stats Today's Range$61.64▼$71.4450-Day Range$62.32▼$116.9752-Week Range$18.56▼$117.75Volume3.33 million shsAverage Volume711,043 shsMarket Capitalization$1.75 billionP/E RatioN/ADividend YieldN/APrice Target$78.14Consensus RatingModerate Buy Company OverviewGeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.Read More… GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 75% of companies evaluated by MarketBeat, and ranked 719th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGeneDx has only been the subject of 3 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth115.46% Earnings GrowthEarnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -31.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -31.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 7.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.03% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently increased by 17.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.03% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently increased by 17.75%, indicating that investor sentiment is decreasing significantly. News and Social Media4.0 / 5News Sentiment1.18 News SentimentGeneDx has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for GeneDx this week, compared to 7 articles on an average week.Search Interest31 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 158% compared to the previous 30 days.MarketBeat Follows7 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,043,288.00 in company stock.Percentage Held by Insiders27.30% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Email Address WGS Stock News HeadlinesInsider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 15,516 Shares of StockApril 11, 2025 | insidertrades.comGeneDx Holdings Corp. (NASDAQ:WGS) Q1 2025 Earnings Call TranscriptMay 1 at 11:04 AM | msn.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 1, 2025 | Stansberry Research (Ad)GeneDx earnings selloff a buying opportunity, says Craig-HallumMay 1 at 11:04 AM | finance.yahoo.comWhy GeneDx Holdings Stock Is Plunging TodayApril 30 at 6:50 PM | finance.yahoo.comGeneDx plunges despite Q1 beat and guidance raiseApril 30 at 6:50 PM | msn.comGeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call TranscriptApril 30 at 2:09 PM | seekingalpha.comGeneDx Holdings Corp. 2025 Q1 - Results - Earnings Call PresentationApril 30 at 1:15 PM | seekingalpha.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $76.86 at the beginning of 2025. Since then, WGS stock has decreased by 18.9% and is now trading at $62.32. View the best growth stocks for 2025 here. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) issued its quarterly earnings results on Wednesday, April, 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.17. The firm earned $87.12 million during the quarter, compared to analysts' expectations of $79.90 million. GeneDx had a positive trailing twelve-month return on equity of 3.33% and a negative net margin of 17.12%. Read the conference call transcript. When did GeneDx's stock split? GeneDx's stock reverse split on the morning of Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? Top institutional investors of GeneDx include Allspring Global Investments Holdings LLC (0.68%), Assenagon Asset Management S.A. (0.38%), New York State Common Retirement Fund (0.31%) and Palisades Investment Partners LLC (0.30%). Insiders that own company stock include Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Jason Ryan, Daniel Emmett Clark, Isaac Ro, Eric Schadt, Karen Ann White, Katherine Stueland, Kevin Feeley, Shawn Assad and Richard Miao. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings4/30/2025Today5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryHealthcare Current SymbolNASDAQ:WGS CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$78.14 High Stock Price Target$118.00 Low Stock Price Target$21.00 Potential Upside/Downside+25.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E Ratio64.25 P/E GrowthN/ANet Income$-175,770,000.00 Net Margins-17.12% Pretax Margin-31.52% Return on Equity3.33% Return on Assets1.69% Debt Debt-to-Equity Ratio0.25 Current Ratio2.40 Quick Ratio2.27 Sales & Book Value Annual Sales$305.45 million Price / Sales5.73 Cash FlowN/A Price / Cash FlowN/A Book Value$8.78 per share Price / Book7.10Miscellaneous Outstanding Shares28,068,000Free Float19,971,000Market Cap$1.75 billion OptionableOptionable Beta1.93 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:WGS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.